home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Palatin Technologies, Inc. Common Stock (NY:PTN)

16.22 -0.10 (-0.61%)

Official Closing Price Updated: 8:00 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Palatin Technologies, Inc. Common Stock

< Previous 1 2 3 4 5 Next >

Palatin Technologies Scores Triple Win with Breakthrough Results in Obesity, Colitis, and Kidney Disease

April 10, 2025

Palatin Technologies Scores Triple Win with Breakthrough Results in Obesity, Colitis, and Kidney Disease

Via News Direct

Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)

March 31, 2025

Via AB Newswire

Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight ↗

March 31, 2025

Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing.

Via Benzinga

Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)

March 31, 2025

Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)

Via News Direct

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

A Look Ahead: Palatin Techs's Earnings Forecast ↗

November 13, 2024

Via Benzinga

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Earnings Preview: Palatin Techs ↗

February 14, 2024

Via Benzinga

Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus ↗

March 28, 2025

Palatin's PL8177 showed promising ulcerative colitis trial results, with strong clinical response rates. FDA granted orphan status to its obesity drug PL7737.

Via Benzinga

Palatin Technologies’ Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)

March 27, 2025

Via AB Newswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 25, 2025

Via Benzinga

On Friday, there are stocks with unusual volume. Let's take a look. ↗

February 07, 2025

Unusual volume stocks in Friday's session

Via Chartmill

Thursday's session: top gainers and losers ↗

February 06, 2025

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Get insights into the top gainers and losers of Monday's after-hours session. ↗

February 03, 2025

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

10 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 14, 2024

Via Benzinga

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 27, 2024

Via Benzinga

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions

August 29, 2024

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions

Via News Direct

PTN Stock Earnings: Palatin Techs Misses EPS for Q3 2024 ↗

May 15, 2024

PTN stock results show that Palatin Techs missed analyst estimates for earnings per share the third quarter of 2024.

Via InvestorPlace

Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying ↗

April 12, 2024

The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested...

Via Benzinga

Topics Stocks

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data ↗

April 08, 2024

Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically significant efficacy in pain reduction and secondary symptoms. PL9643...

Via Benzinga

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 28, 2024

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

February 28, 2024

Via Benzinga

Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets ↗

February 28, 2024

Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondary endpoints did not reach statistical significance.

Via Benzinga

Dow Dips 200 Points; TJX Posts Upbeat Sales ↗

February 28, 2024

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

February 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 15, 2024

Via Benzinga

The 3 Best Penny Stocks to Buy in February 2024 ↗

February 15, 2024

With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.

Via InvestorPlace

7 Analyst-Backed Stocks With Promising 10-Bagger Potential ↗

February 01, 2024

Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com